Value of positron emission tomography for lung cancer staging

European Journal of Surgical Oncology

Volumn 28, Issue 1, 2002, Pages 55-62

  Albes, Johannes M ^a,b   Dohmen, B M ^a   Schott, U ^a   Schulen E ^a   Wehrmann, M ^a   Ziemer, G ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

2 18F fluoro 2 deoxyglucose; Computed tomography; Non small cell lung cancer; Positron emission tomography; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADENOCARCINOMA; ARTICLE; BONE SCINTISCANNING; BRONCHOSCOPY; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE; LYMPHADENECTOMY; MEDIASTINOSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LUNG TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0036483995     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2001.1144     Document Type: Article

References (29)

1. Miller BA, Ries LAG, Hankey BF, et al. (eds) SEER Cancer Statistics Review: 1973-1990. National Cancer Institute. NIH Pub. No. 93-2789, 1993.
2. Patterson GA. Lung cancer staging. Chest 1991; 100: 520-2.
3. Little AG, Stitik FP. Clinical staging of patients with non-small cell lung cancer. Chest 1990; 97: 1431-8.
4. Sarinas PS, Chitkara RK, Buadu EO, Gould MK, Kuschner WG, Segall GM. Usefulness of positron emission tomography imaging in the management of lung cancer. Curr Opin PuIm Med 1999; 5: 201-7.
5. Steinert HC, Schulthess GK, Weder W. Effektivität der Ganzkörper-PET mit FDG beim Staging des nicht-kleinzelligen Bronchuskarzinoms bei 100 Patienten. Nuklearmedizin 1998; 4: A37.
6. Lowe VJ, Naunheim KS. Positron emission tomography in lung cancer. Ann Thorac Surg 1998; 65: 1821-9.
7. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
8. Kubota K, Matzusawa T, Ito M, et al. Lung tumor imaging by positron emission tomography using C-11 L-methionine. J Nucl Med 1985; 26: 37-42.
9. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60: 2682-9.
10. Kubota K, Matsuzawa T, Ito M, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31: 1927-32.
11. Lewis P, Griffin S, Marsden P, et al. Whole body 18F-fluorodesoxyglucose positron emission tomographie in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-6.
12. Duhaylongsod FG, Lowe VJ, Patz EF Jr, et al. Detection of primary and recurrent lung cancer by means of I8F fluorodesoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995; 110: 130-40.
13. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996; 111: 642-8.
14. Albes JM, Lietzenmayer R, Schott U, et al. Improvement of non-small-cell lung cancer staging by means of positron emission tomography. Thorac Cardiovasc Surgeon 1999; 47: 42-7.
15. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG-PET versus CT with correlative lymph node - mapping and sampling. Radiology 1997; 202: 441-6.
16. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 1996; 9: 2560-4.
17. Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske SN. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). Thorax 1997; 52: 438-41.
18. Saunders CAB, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999; 67: 790-7.
19. Kotserke J, Guhlmann A, Moog F, Frickhofen N, Reske SN. Role of attenuation correction for fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med 1999; 26: 31-8.
20. Zasadny KR, Kison PV, Quint LE, Wahl RL. Untreated lung cancer: quantification of systemic distortion of tumor size and shape on non-attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET scans. Radiology 1997; 204: 279.
21. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996; 23: 741-7.
22. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s: meta analytic comparison of PET and CT. Radiology 1999; 213: 530-6.
23. Berlangieri SU, Scott AM, Knight SR, et al. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg 1999; 16 (Suppl. 1): S25-S30.
24. Wahl RL, Quint LE, Greenbough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371-7.
25. Gupta NC, Graeber GM, Rogers JS 2nd, Bishop HA. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg 1999; 229: 286-91.
26. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluorodeoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol 1999; 17: 3201-6.
27. Coates G, Skehan SJ. Emerging role of PET in the diagnosis and staging of lung cancer. Can Respir J 1999; 6: 145-52.
28. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F] fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small-cell-lung cancer) in Japan. Chest 2000; 117: 346-53.
29. Farrell MA, McAdams HP, Herndon JE, Patz EF Jr. Non-small-cell-lung cancer: FDG-PET for nodal staging in patients with stage I disease. Radiology 2000; 215: 886-90.